MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.

Caglar UnalTolga ÖzmenAhmet Serkan İlgünÇetin OrduEnver ÖzkurtNaziye AkGül AlçoZeynep Erdoğan İyigünSevgi KurtTomris DuymazMehmet Alper ÖztürkFiliz Elbüken ÇelebiKanay YararbaşGürsel SoybirFatma AktepeVahit Özmen

Published in: Breast cancer (Dove Medical Press) (2023)

Our study is the first study in the literature to investigate the relationship between ODX-RS and MCM-2 levels in HR-positive HER-2 negative early breast-cancer patients. In this study, MCM-2 was an independent risk factor in identifying high-risk patients according to TAILORx risk classification. MCM 2 cut-off value (50) may help the decision on adjuvant chemotherapy in patients where the Oncotype DX test cannot be performed.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
machine learning
deep learning
systematic review
peritoneal dialysis
risk factors